文献速递心境障碍儿童青少年精神

青少年抑郁症症状簇与治疗差异反应:TADS试验二次分析

Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
PubMed 文献 · Lancet Psychiatry · 2020-01-01

该研究基于TADS随机试验中439名12-17岁重性抑郁障碍青少年的数据,采用Ward聚类法识别出两个症状簇,并用线性混合效应模型分析症状簇与12周急性期治疗疗效的关系。结果显示,氟西汀联合CBT和氟西汀单药对簇1症状的改善显著优于安慰剂,而簇2症状在各治疗组与安慰剂组间无显著差异。

要点

  • 识别出两个症状簇:簇1以抑郁心境、快感缺失、易激惹等为核心,簇2以食欲改变、躯体不适、自杀意念等为核心。
  • 氟西汀联合CBT和氟西汀单药对簇1症状的CDRS-R评分改善显著优于安慰剂。
  • 簇2症状在活性治疗组与安慰剂组间未检测到显著改善差异。

核心结论

  • 青少年抑郁症患者对氟西汀和CBT的治疗反应具有异质性,不同症状簇对治疗的反应不同。
  • 临床医生在选择治疗模式时应考虑患者的临床特征,针对特定症状开发新疗法可能提高疗效。

研究设计与样本

  • 二次分析使用TADS随机试验数据,纳入439名12-17岁美国青少年,DSM-IV重性抑郁障碍且CDRS-R最低45分。
  • 受试者按1:1:1:1随机分配至氟西汀、CBT、氟西汀联合CBT或安慰剂组,分析聚焦试验前12周急性期。
  • 采用Ward法和欧氏距离层次凝聚聚类,基于基线CDRS-R各条目评分建立症状簇,再用线性混合效应模型分析症状簇与疗效关系。

主要发现

  • 识别出两个症状簇:簇1包括抑郁心境、难有乐趣、易激惹、社交退缩、睡眠障碍、学业受损、过度疲劳和低自尊;簇2包括食欲增加、躯体不适、过度哭泣、食欲下降、过度内疚、病态观念和自杀意念。
  • 对于簇2症状,活性治疗组与安慰剂组间未检测到CDRS-R评分改善的显著差异。

关键数值与推荐

  • 簇2症状:活性治疗与安慰剂组间CDRS-R评分改善无显著差异。

临床怎么用

  • 临床选择青少年抑郁症治疗模式时,应考虑症状簇特征,簇1症状可能对氟西汀联合CBT或氟西汀单药反应更好。
  • 针对簇2症状(如食欲改变、躯体不适、自杀意念等),现有氟西汀和CBT方案疗效不显著,需关注并探索针对性干预。

局限性

  • 本研究为TADS试验的二次分析,结果需在独立样本中验证。
  • 分析仅聚焦急性期前12周,未涵盖长期治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Better understanding of the heterogeneity of treatment responses could help to improve care for adolescents with depression. We analysed data from a clinical trial to assess whether specific symptom clusters responded differently to various treatments. METHODS: For this secondary analysis, we used data from the Treatment for Adolescents with Depression Study (TADS), in which 439 US adolescents aged 12-17 with a DSM-IV diagnosis of major depressive disorder and a minimum score of 45 on the Children's Depression Rating Scale-Revised (CDRS-R) were randomly assigned (1:1:1:1) to treatment with fluoxetine, cognitive behavioural therapy (CBT), fluoxetine plus CBT, or pill placebo. Our analysis focuses on the acute phase of the trial (ie, the first 12 weeks). Groups of co-occurring symptoms were established by clustering scores for each CDRS-R item at baseline with Ward's method, with Euclidean distances for hierarchical agglomerative clustering. We then used a linear mixed-effects model to investigate the relationship between symptom clusters and treatment efficacy, with the sum of symptom scores within each cluster as the dependent measure. As fixed effects, we entered cluster, time, and treatment assignment, with all two-way and three-way interactions, into the model. The random effect providing better fit was established to be a by-subject random slope for cluster based on improvement in the Schwarz-Bayesian information criterion. OUTCOMES: We identified two symptom clusters: cluster 1 comprised depressed mood, difficulty having fun, irritability, social withdrawal, sleep disturbance, impaired schoolwork, excessive fatigue, and low self-esteem, and cluster 2 comprised increased appetite, physical complaints, excessive weeping, decreased appetite, excessive guilt, morbid ideation, and suicidal ideation. For cluster 1 symptoms, CDRS-R scores were reduced by 5·8 points (95% CI 2·8-8·9) in adolescents treated with fluoxetine plus CBT, and by 4·1 points (1·1-7·1) in those treated with fluoxetine, compared with those given placebo. For cluster 2 symptoms, no significant differences in improvements in CDRS-R scores were detected between the active treatment and placebo groups. INTERPRETATION: Response to fluoxetine and CBT among adolescents with depression is heterogeneous. Clinicians should consider clinical profile when selecting therapeutic modality. The contrast in response patterns between symptom clusters could provide opportunities to improve treatment efficacy by gearing the development of new therapies towards the resolution of specific symptoms. FUNDING: Conselho Nacional de Desenvolvimento Científico e Tecnológico.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bondar J, Caye A, Chekroud AM, et al. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial. Lancet Psychiatry. 2020. PMID: 32199509. doi:10.1016/S2215-0366(20)30060-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。